NOV 18, 2017 02:29 PM PST

Targeting Prostate Specific Membrane Antigens in Renal Cell Carcinoma

WRITTEN BY: Courtney Schaal
3 4 206

Prostate Specific Membrane antigens (PSMA) encoded by the gene FOLH1, and also known as glutamate carboxypeptidase 2, are transmembrane proteins that have had great utility in the molecular imaging of prostate cancer using positron emission tomography (PET) and detecting its presence, as well as being targeted by small molecules with radionuclides, and exploited therapeutically.  PSMA is expressed normally in non-malignant prostate epithelial cells, but is well known to be upregulated in prostate tumors.  Aside from being expressed in cells of the prostate, PSMA is expressed by endothelial cells including those of the vasculature networks of other solid tumors such as renal cell carcinoma (RCC).

RCC is the most common type of kidney cancer occurring in adults, accounting for nearly 95% of all cases.  Patients presenting with localized RCC typically undergo partial or in some cases complete removal of the effected kidney, and have a survival rate of 65-90%.  This number decreases dramatically if the disease has advanced and metastasized to other organs.  As with many cancers, typically by the time a RCC patient presents in the clinic they have advanced disease.  This is largely because RCC tends to be asymptomatic until later stages of progression, so determining markers for early detection would be valuable and potentially life-saving.  Two scientists at the James Buchanan Brady Urological Institute and Department of Urology at Johns Hopkins University in Baltimore, Maryland have utilized the fact that PSMA is expressed in the neovasculature of RCC, and used PSMA-targeted PET radio labels to successfully image RCC in their patients, and with greater sensitivity than traditional imaging modalities allowing them to detect metastatic disease in clear cell RCC (ccRCC).  Further, Sophia Spatz, a researcher at the Clinic of Urology, University Hospital Bonn in Bonn, Germany, and her colleagues published findings that PSMA was not only expressed in a cohort of 257 RCC patient tumors by histological staining, but the levels of expression correlated with disease stage and grade, as well as overall survival.  These findings were further confirmed by RNA expression data from The Cancer Genome Atlas.

These reports lend evidence that PSMA may also have utility in diagnostic imaging and therapeutic targeting in RCC in addition to its more traditional use in prostate cancer.  If it could be effectively targeted in RCC, this holds potential to offer a therapeutic intervention even for advanced disease for which there are currently no good treatment options, and to date remains incurable.    

Sources: Nature Reviews Urology, Wikipedia, Journal of Urology, Pixabay, Youtube/Health Tips

 

 

 

 

About the Author
You May Also Like
MAR 25, 2018
Drug Discovery
MAR 25, 2018
New Drug 'Siponimod' Seeks to Treat Secondary Progressive MS
Multiple sclerosis (MS) is an autoimmune disease of the central nervous system where the affected individual’s immune system cells eradicate the myel
MAR 25, 2018
Drug Discovery
MAR 25, 2018
The Next Step Treatment for Hookworm Infections
Researchers have discovered a crucial step in blood digestion of hookworms that feed and infect the blood of mice. The key step can be targeted to disrupt
APR 10, 2018
Drug Discovery
APR 10, 2018
'Melting Away' Chronic Lymphocytic Leukemia (CLL)
Chronic lymphocytic leukemia (CLL) is a form of cancer that that first occurs in the cells that become certain white blood cells (called lymphocytes) which
MAY 08, 2018
Drug Discovery
MAY 08, 2018
Developing a Drug For Genetic Obesity
Researchers from the Institute for Experimental Pediatric Endocrinology of the Charité -- Universitätsmedizin Berlin have fortunately treated p
JUL 17, 2018
Drug Discovery
JUL 17, 2018
Potential AML Drug Encourages Cancer Cell Mapping
International researchers have sought to be the first in mapping family trees of cancer cells in acute myeloid leukemia (AML) to help them understand how t
AUG 15, 2018
Drug Discovery
AUG 15, 2018
Experimental Drug May Treat The Chronic Itch
Investigators at the University of Zurich have discovered a new approach that treats the chronic itch thanks to two receptors in the spinal cord and the ri
Loading Comments...